ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2468

Antibodies to Histocompatibility Antigens in Juvenile Systemic Lupus Erythematosus Patients

Ana L Rodríguez-Lozano1, Anne M. Stevens2, Jessica M Foster3, Marisa S. Klein-Gitelman4, Hermine I. Brunner5, Elizabeth Field6, Ann M Reed7 and Karen Onel8, 1Immunology, Instituto Nacional de Pediatria, Mexico City, Mexico, 2Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, 3Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, 4Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Internal Medicine, University of Iowa, Iowa City, IA, 7Department of Pediatrics, Duke University, Durham, NC, 8Pediatric Rheumatology, Univ of Chicago, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, juvenile SLE, major histocompatibility complex (MHC) and nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Pediatric Rheumatology - Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Microchimerism with HLA mismatched maternal cells can be readily demonstrated in normal individuals and is now established as a normal biological phenomenon.  Pediatric SLE patients have decreased levels of blood maternal microchimerism, suggesting a loss of T-cell tolerance to maternal antigens.   Because maternal MHC molecules are the most likely targets of the T-cell hyperactivity, we reasoned that pediatric lupus patients may also have B cell reactivity to maternal MHC.  

Methods:

To test for loss of B-cell tolerance to maternal MHC, we measured IgG specific for HLA Class II antigens in plasma samples from children who have never been pregnant:  81 with SLE (49 (60%) with active disease, SLEDAI >4), 20 patients (24%) with nephritis.   Control groups consisted of 16 systemic sclerosis (SSc), 20 juvenile idiopathic arthritis (JIA), and 78 healthy children.  OneLambda, Inc. LABScreen microbeads coated with purified Class II HLA antigens were used to detect specific IgG. Data acquisition and analysis was performed using LABScan™ Statistical analysis was performed using SPSS version 16.0, Mann Whitney was used to determine median difference between groups, Correlations were tested by Spearman and associations by Likelihood ratios or Fisher Exact Test, ROC curves were constructed to test for the specificity of HLAab for lupus diagnosis and active lupus. 

Results: All Subjects:  The median values of 90% of specific HLAab were high in patients with SLE compared to controls.  HLAab levels in JIA and SSc were similar to controls. Among the SLE patients, 27 out of 77 HLA antigens were increased in patients with active disease compared to those without active disease.  Of these, a significant association was found with disease activity in 15 HLAab (see Table 1).  ROC curves demonstrated specificity for active SLE in 4 HLAab, with AUC >.700: DQA1*0301-DQB1*0302 (AUC .758, 95% CI 0.66-.86, p<0.001), DQA1*0301-DQB1*0303, (AUC 0.76, 95% CI 0.66-.87, p<0.001), DQA1*0501-DQB1*0201 (AUC 0.73, 95% CI 0.61-.84, P=0.001, and DPB1*1401=DPA1*0201 (AUC 0.72, 95% CI 0.6-.84], P=0.001. Ten HLAab demonstrated a significant median difference between those with and without nephritis, and seven of those showed significant associations (Table 1).

Conclusion:

Children with SLE have high values and a considerable number of anti-HLA class II autoantibodies which seem to be specific, related with disease activity and to a lesser extent with nephritis.   If confirmed, HLAab could represent useful biomarkers for disease activity. 

Table 1. Significant association between HLAab with Disease Activity and Nephritis

HLAab

Disease Activity

 

HLAab

Nephritis

DQA*10301 DQB*10302

15.948 sig .000&

 

DQA1*0303 DQB1*0401

5.806 sig .020&

DQA*10301 DQB*10303

12.7888 sig .000

 

DQA1*0101 DQB1*0501

5.330 sig .023&

DPB1*1401 DPA1*0202

11.401 sig .001

 

DPB1*1001 DPA1*0201

5.131 sig .024

DQA1*0401 DPB1*0201

10.960 sig .001&

 

DRB5*0202

4.751 sig .045&

DPB1*1001 DPA1*0201

10.246 sig .001

 

DQA1*0102 DQB1*0609

4.489 sig .037&

DQA1*0302 DQB1*0301

9.773 sig .008&

 

DQA1*0201 DQB1*0201

4.322 sig .036&

DQA1*0601 DQB1*0301

8.608 sig .014&

 

DQA1*0201 DQB1*0202

4.322 sig .036&

DQA1*0303 DQB1*0301

8.608 sig .014&

 

 

 

DRB1*1303

8.608 sig .014&

 

 

 

DQA1*0501 DQB1*0201

8.359 sig .004

 

 

 

DQA1*0201 DQB1*0303

7.906 sig .005

 

 

 

DRB1*1001

7.465 sig .025&

 

 

 

DPB1*0301 DPA1*0103

7.105 sig .008

 

 

 

Associations between Disease Activity (SLEDAI>4) and Nephritis with HLAab are reported as Likelihood Ratios and Fisher Exact Test&


Disclosure: A. L. Rodríguez-Lozano, None; A. M. Stevens, None; J. M. Foster, None; M. S. Klein-Gitelman, None; H. I. Brunner, None; E. Field, None; A. M. Reed, None; K. Onel, None.

To cite this abstract in AMA style:

Rodríguez-Lozano AL, Stevens AM, Foster JM, Klein-Gitelman MS, Brunner HI, Field E, Reed AM, Onel K. Antibodies to Histocompatibility Antigens in Juvenile Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/antibodies-to-histocompatibility-antigens-in-juvenile-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-to-histocompatibility-antigens-in-juvenile-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology